ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1167

Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study

Kanako Chujo1, Hiromi Shimada2, Shusaku Nakashima2, Taichi Miyagi1, Koichi Sugihara2, Yusuke Ushio1, Mao Mizusaki2, Naoto Manabe1, Mayuko Wada2, Risa Wakiya3, Hiroki Ozaki4 and Hiroaki Dobashi2, 1Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, 3Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, 4KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan

Meeting: ACR Convergence 2025

Keywords: IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Treatment of IgG4-related disease (IgG4-RD) is recommended for patients with severe organ involvement or for patients with reduced quality of life even in the absence of severe organ involvement. On the other hand, some patients with no severe lesions and acceptable quality of life, especially those with asymptomatic single organ disease, can be followed up without treatment. Therefore, we aimed to investigate the clinical characteristics and outcomes of patients without therapeutic intervention at the time of IgG4-RD diagnosis in single center.

Methods: Patients with IgG4-RD diagnosed from 2005 to 2024 according to the comprehensive diagnostic criteria for IgG4-RD revised in 2020 at our institution were included in our study. Clinical characteristics including IgG4-RD Responder Index (IgG4-RD RI) and immunological laboratory findings were retrospectively collected from medical records. In the cases observed without treatment after IgG4-RD diagnosis, we investigated whether the subsequent therapeutic intervention became necessary or not. We then analyzed the predictors of the need for treatment.

Results: Of all 80 cases diagnosed with IgG4-RD, 54 cases (67.5%) were started to treat at diagnosis (treatment group), while 26 cases (32.5%) were observed without therapeutic intervention (observation group).In the observation group, age at diagnosis was significantly younger and the levels of CRP, IgG, sIL-2R and IgG4-RD RI were lower. Serum IgG4 levels also tended to be lower compared to the treatment group (Table 1). Cases with only glandular and lymph node involvement were more common in the observation group. In contrast, patients with severe organ involvement such as retroperitoneal, renal, pancreatic, pulmonary and orbital lesions were more likely to have started treatment at the time of diagnosis (Figure 1).Of the 26 cases in the observation group, 7 required therapeutic intervention during the observation period. New organ involvement, including the pancreas, was observed in 5 cases. There were no significant differences in clinical characteristics at the time of diagnosis between the patients with (n=7) and without (n=19) treatment intervention (Table 2). The mean duration from diagnosis to the initiation of therapeutic intervention was 30 ± 25 months. Among the 19 cases without treatment intervention, 13 cases (68.4%) had multiple organ involvement, such as glandular, lymph node, and pulmonary involvement.

Conclusion: In our study, some cases of IgG4-RD could be observed without treatment, even with multiple lesions. It is important to have an appropriate monitoring strategy to determine the need for therapeutic intervention in IgG4-RD.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Chujo: None; H. Shimada: None; S. Nakashima: None; T. Miyagi: None; K. Sugihara: None; Y. Ushio: None; M. Mizusaki: None; N. Manabe: None; M. Wada: None; R. Wakiya: None; H. Ozaki: None; H. Dobashi: None.

To cite this abstract in AMA style:

Chujo K, Shimada H, Nakashima S, Miyagi T, Sugihara K, Ushio Y, Mizusaki M, Manabe N, Wada M, Wakiya R, Ozaki H, Dobashi H. Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/clinical-characteristics-and-outcomes-of-igg4-related-disease-patients-who-chose-watchful-observation-without-treatment-intervention-a-single-center-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-and-outcomes-of-igg4-related-disease-patients-who-chose-watchful-observation-without-treatment-intervention-a-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology